Nuclear import of factors involved in signaling is inhibited in C3H/10T1/2 cells treated with tetradecylthioacetic acid

Bodil Bjørndal,† Charlotte Helleland,† Stig-Ove Bøe,† Oddrun A. Gudbrandsen,§ Karl-Henning Kalland,‡ Pavol Bohov,§,** Rolf K. Berge,§ and Johan R. Lillehaug*

Department of Molecular Biology,* University of Bergen, 5020 Bergen, Norway; Department of Microbiology and Immunology,† University of Bergen, Norway; Department of Clinical Biochemistry,§ University of Bergen, Norway; and Institute of Experimental Endocrinology,** Slovak Academy of Sciences, Bratislava, Slovak Republic

Abstract The non-β-oxidisable tetradecylthioacetic acid (TTA) is incorporated into cellular membranes when C3H/10T1/2 cells are cultured in TTA-containing medium. We here demonstrate that this alteration in cellular membranes affect the nuclear translocation of proteins involved in signal transduction. Analysis of cellular fatty acid composition shows that TTA and TTA:1n-8 constitute approximately 40 mol% of total fatty acids in cellular/nuclear membranes. Activation of c-fos expression is significantly inhibited in TTA-treated cells but the enzymatic activation of mitogen activated protein kinase (ERK) is not affected. Immunofluorescence and confocal microscopy studies demonstrate that in mitogene-stimulated TTA-treated cells, the translocation of phosphorylated ERK1/2, protein kinase Cα (PKCα), and PKCβ1 from the cytoplasm into the nucleus is considerably decreased and delayed. Concomitant with a decreased nuclear import, ERK1/2 phosphorylation is decreased in TTA-treated cells. There is no TTA-induced inhibition of nuclear import of proteins with a classical nuclear localization signal (NLS), as seen by in vitro nuclear import experiments of BSA fused to the NLS from SV40 large T, or in vivo studies of hnRNP A1 nuclear import. The expression levels of Importin α, Importin β, Importin 7, and NTF2 are not altered in the TTA-treated cells.† Taken together, our data indicate that TTA treatment causes changes in cellular fatty acid composition that negatively affect NLS-independent mechanisms of protein translocation through the nuclear pore complex.—Bjørndal, B., C. Helleland, S-O. Bøe, O. A. Gudbrandsen, K-H. Kalland, P. Bohov, R. K. Berge, and J. R. Lillehaug. Nuclear import of factors involved in signaling is inhibited in C3H/10T1/2 cells treated with tetradecylthioacetic acid. J. Lipid Res. 2002. 43: 1630–1640.

Supplementary key words TTA • mitogen-activated protein/extracellular signal-regulated kinase • protein kinase C • nuclear translocation

We have investigated the metabolic effects of a novel sulfur-substituted fatty acid analog, tetradecylthioacetic acid [CH₃(CH₂)₁₃S-CH₃COOH] (TTA), that has major impact on cellular metabolism (1, 2). TTA has many chemical and physical properties in common with normal saturated fatty acids, but it cannot undergo β-oxidation (1). When administered to rats, TTA promotes hepatic peroxisome and mitochondria proliferation and decreases serum triacylglycerol, cholesterol, and free fatty acid levels (3–5). TTA is known to affect the expression and activity of several genes involved in lipid metabolism (5–11), and is incorporated into liver lipids and plasma lipoproteins. We have previously found that TTA increases the formation of phosphatidylethanolamine (PE) with a shift from less to more polar molecular species in fibroblasts, and that TTA attenuates PDGF- and 12-O-tetradecanoyl phorbol-13-acetate (TPA)-induced c-fos mRNA expression (12). Altogether, TTA seems to alter the lipid composition in the cells in a manner that effects the PDGF- and TPA-induced signal transduction pathway leading to the regulation of c-fos mRNA expression.

The mitogen-activated protein kinase (MAPK) cascades are essential for signaling of various extracellular stimuli to the nucleus, and the Ras-mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)-mitogen-activated protein/extracellular signal-regulated kinase (ERK) pathway is important in regulating c-fos transcription. The triggering step in this pathway is the translocation of ERK1 and ERK2, also known as p44 and p42 MAPK, respectively, from the cytoplasm to the nucleus (13–15), where they activate nuclear factors such as Elk-1 by phosphorylation (16). Activation and nuclear translo-

Abbreviations: DAG, diacylglycerol; ERK, mitogen-activated protein/extracellular signal-regulated kinase; MEK, mitogen-activated protein/extracellular signal-regulated kinase; NLS, nuclear localization signal; NPC, nuclear pore complex; PDGF-BB, platelet-derived growth factor-BB; PE, phosphatidylethanolamine; PKC, protein kinase C; TPA, 12-O-tetradecanoyl phorbol-13-acetate; TTA, tetradecylthioacetic acid.

† To whom correspondence should be addressed.
e-mail: bodil.bjorndal@mbi.uib.no

12-0-Tetradecanoyl phorbol-13-acetate; TTA, tetradecylthioacetic acid.
cation of ERK1/2 is required for mitogen-induced gene expression and cell cycle re-entry (17), making nuclear translocation a critical step in signal transduction. Unphosphorylated ERK is believed to be retained in the cytoplasm by complexing with proteins such as MEK (MAPK kinase) (18) and protein tyrosine phosphatase PTP-SL (19). The phosphorylation of ERK by MEK results in the dissociation of the ERK-MEK complex (18). The subsequent import mechanism has been most extensively studied for ERK2; three mechanisms have been identified: passive diffusion of a monomer, active transport of a phosphorylated ERK2 dimer (20, 21), or a recently discovered third pathway where ERK can be imported into the nucleus by direct contact with the nuclear pore complex (NPC) independent of phosphorylation, energy, or transport factors (22, 23). However, the exact mechanism by which ERK1/2 passes through nuclear pores has not been fully elucidated, and ERK does not contain a classical nuclear localization signal (NLS). Taken together, ERK enzyme activation and nuclear translocation are separable events (24). Stimulating the cells with TPA or platelet-derived growth factor-BB (PDGF-BB) showed that the ERK activity was the same in both control and TTA-treated cells. These results indicated that the pathway(s) activating ERK was not altered by the 3-thia fatty acid. Indirect immunofluorescence of total ERK1/2 and activated pERK1/2 showed, however, that the translocation of pERK1/2 from cytoplasm to the nucleus was significantly reduced in TTA-treated cells.

Recently, we have demonstrated that protein kinase C (PKCa) and PKCb, in C3H/10T1/2 cells are translocated from the cytoplasm to the nucleus in response to TPA stimulation, but not in response to PDGF-BB stimulation (25). In this study we showed that this nuclear translocation of PKCa and PKCb was reduced in TTA-treated cells compared with control cells. Thus, other PKs involved in signal transduction were affected by TTA, and the inhibition of nuclear import was not unique to ERK. To further investigate the mechanism of the TTA-inhibition, a classical, lysine-rich NLS from SV40 large T antigen was coupled to BSA-fluorescein (FITC) and used to study nuclear import in digitonin-permeabilized cells. Neither the import kinetics of BSA fused to this strong NLS, nor the in vivo import of the NLS (M9)-containing protein hnRNP A1 was detectably inhibited in TTA-treated cells. Our results suggest that nuclear import of proteins without a classical NLS is inhibited in TTA-treated cells while NLS-directed import is unaffected.

MATERIALS AND METHODS

Cell cultures

The mouse embryo fibroblasts C3H/10T1/2C1 8 (10T1/2) have been described previously (26). TTA was synthesized as previously described (1). Cells were seeded in basal minimal Eagle’s medium (BMEM; GIBCO BRL) supplemented as described (25). After 24 h, TTA (20 μM, final concentration) was added to the appropriate cell cultures, and an equal amount of acetone was added to the control cultures. After 48 h the medium was changed to UltraMem (Bio Whittaker, Inc., Walkersville, MD) supplemented with 2% FCS containing 20 μM TTA (final concentration)/acetone. By analysis, TTA comprised 54 mol% of total fatty acids in the growth medium. The medium was changed every second or third day until the cells had reached confluence. Cells to be used for indirect immunofluorescence assays were at confluence trypsinized and reseeded onto coverslips (Merch Eurolab, Darmstadt, Germany) at a concentration of 10,000 cells per well. The cells were then grown for 3 days in UltraMem medium containing TTA/acetone before they were stimulated and fixed for subsequent indirect immunofluorescence assays.

Materials and antibodies

TPA from Sigma Chemical Co. (St. Louis, MO) was dissolved in acetone. Porcine platelet-derived growth factor (PDGF-BB) and Actinomycin D was from Sigma. Leptomycin B was a generous gift from Dr. Barbara Wolff (Sandoz Research Institute, Vienna, Austria). Rabbit polyclonal antibodies against ERK1 (H-8), ERK2 (D-2), c-PKCa (C-20), and c-PKBb1 (C-16) were from Santa Cruz Biotechnologies (Santa Cruz, CA), and the monoclonal antibody to phospho-p44/p42 MAPK (E10, pERK1/2) was from New England Biolabs, Inc. (Beverly, MA). Monoclonal anti-hnRNP A1 (4B10) was the generous gift of professor Gideon Dreyfuss (University of Pennsylvania School of Medicine, Philadelphia, PA). FITC-conjugated goat-anti-rabbit IgG and goat-anti-mouse was from Southern Biotechnology Associates, Inc. (Birmingham, AL), and Alexa568-conjugated goat-anti-mouse was from Molecular Probes. Biotin-conjugated rabbit-anti-mouse and FITC-conjugated streptavidine were from Amersham Int. plc.

ERK activity determination

Cells were grown to confluence on 100 mm plastic culture dishes with final medium change 24 h prior to harvesting. Cells were stimulated with 1 unit of PDGF-BB for the appropriate time. 1 unit of PDGF-BB corresponds to the amount of stimulant giving half-maximal stimulation of DNA synthesis. Cells were washed three times with cold phosphate buffered saline (PBS) and lysed in 0.5 ml non-ionic detergent buffer (1% Triton X-100, 20 mM TrisHCl, pH 8.0, 157 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM PMSF, 50 mM sodium fluoride and 1 mM sodium orthovanadate), by gentle rocking for 20 min at 4°C. To amounts of cell lysate corresponding to 100 μg total protein, MAPK antibody (anti-ERK1, 1:100, v/v) was added and incubated for 2 h at 4°C. Twenty microliters protein A/G PLUS agarose-conjugate (Santa Cruz) was added for the last 30 min. Immuno-complexes were collected by micro-centrifugation, and washed twice in non-ionic detergent buffer and once in TBS containing 5 mM benzamidine, 1 mM sodium orthovanadate. MAPK activity was determined by addition of 40 μl of kinase reaction mixture containing 30 mM TrisHCl, pH 8.0, 10 mM MgCl2, 20 μM ATP, 1 mM DTT, 5 mM benzamide, 10 μg of [γ-32P]ATP (specific activity 3,000 Ci/mmol, Amersham), and 6 μg myelin basic protein (MBP) (Upstate Biotechnology, NY). After 30 min incubation at 37°C, the reaction was stopped by adding 20 μl sample buffer and samples were subjected to SDS-PAGE. The gel was fixed in 10% acetic acid, 50% ethanol for 30 min and vacuum dried for 2 h at 80°C. The gel was subjected to phospho-imager analyses (Instant Imager, Packard Electronic Autoradiography/ Instant Image Scanning) and exposed to X-Ray film.

Indirect immunofluorescence and immunoblot analysis

The cells used for immunofluorescence were grown on glass coverslips, treated with 10% FBS, TPA (1.7 μM), or PDGF-BB (1 unit), and washed once at 37°C with a cytoskeleton buffer (CB).

Bjørndal et al. TTA affects nuclear protein translocation 1631
(137 mM NaCl, 5 mM KCl, 1.1 mM Na$_3$HPO$_4$·2H$_2$O, 0.4 mM KH$_2$PO$_4$, 5.5 mM glucose, 4 mM NaHCO$_3$, MES, pH 6.1, 2 mM EGTA, and 2 mM MgCl$_2$). Cells were fixed for 20 min at room temperature with 3.7% formaldehyde in CB, washed three times 10 min in PBS and then permeabilised for 10 min in 0.1% Triton-X-100 in PBS. Cells were then incubated for 30 min with blocking solution (1% BSA in PBS) before incubation with antibodies against ERK1 (1:1,000, v/v), ERK2 (1:500, v/v), pERK1/2 blocking solution (1% BSA in PBS) before incubation with anti-

temperature with 3.7% formaldehyde in CB, washed three times in ice-cold PBS prior to harvesting. The cells were incubated with TPA or 10% FBS for the appropriate time, washed three times in ice-cold PBS and lysed in non-ionic detergent buffer (1% triton X-100, 20 mM Hepes pH 7.4, 110 mM KAc, 2 mM MgCl$_2$, and 0.5 mM EDTA). Permeabilization of cells was then carried out on ice for 7 min in the presence of buffer T containing 40 μg/ml digitonin (Sigma). Following an additional wash in buffer T, coverslips were inverted onto 25 μl reaction mixture consisting of 1.1 mM ATP, BSA-NLS-FITC (between 0.2 and 1.0 μM), and reticulocyte lysate (Promega, Madison, WI), 1:4, v/v. In control reactions, the reticulocyte lysate was replaced with buffer T. The reactions were performed for 5 to 30 min in a humidified chamber at 37°C and then terminated by fixation in 3.7% formaldehyde in PBS. Finally, cells were washed in PBS and mounted on slides.

**Dot blot analysis**

Dot blot was performed as described in Fluge et al. (32). PCR products were amplified from cDNA from 10T1/2-cells using specific primers (Eurogentec, Seraing, Belgium) for Importin α (F-TGATGATGCTATTTCTCGGCTAGCA, R-ATTGTTGGCTGAGGTGCGATGCACTA), Importin β (F-AGCAGAGGTGGCTGCTATGTTAG, R-AAGGGTTCCAGTCTAGCTGTTG), Importin 7 (F-GATAACAAATATGGCCTGATCGG, R-GGCGCCATATATTGTTCCTGTTGATC), Nuclear Transport Factor 2 (NTF2, 5'-GGCAAGAACATATTGGCCTGATCGG, R-GGCGCCATATATTGTTCCTGTTGATC), and Actin (F-GGCCACACCCTTCATACA, R-AAGGAGGGTGTGAAGAGTG). The [α-32P]dCTP (Amersham) labeled probes were generated by first-strand cDNA synthesis from total RNA isolated from 10T1/2-cells pre-treated with TTA or acetone as described previously (32). The hybridised membranes were subjected to phospho-imaging (FLA 2000, Fujifilm, Düsseldorf, Germany) overnight, and exposed to X-Ray film. Image Gauge (version 3.4.1) was used to quantify the results from phospo-imaging.

**RESULTS**

**TTA-treatment of 10T1/2 cells does not effect ERK enzyme activation**

We previously showed that TTA attenuates the expression of c-fos mRNA in response to mitogenic activators (12). As several of the early steps in cell signaling involve membrane-associated factors, we studied the mitogen-mediated activation of the downstream factor ERK in the MAPK pathway. ERK1 was fully activated in response to platelet derived growth factor -BB (PDGF-BB) treatment (Fig. 1), 10% FCS, or the phorbol ester TPA (results not shown) in TTA-treated cells compared with control cells, indicating that the signal-transduction pathway leading to ERK activation was not affected by TTA in 10T1/2 cells. The ERK1 antibody used in this study has been used to have some cross-specificity for ERK2. The anti-ERK1 bound similar amounts of ERK1 and ERK2 when 10T1/2 cell-lysate was subjected to SDS-PAGE and subsequently immunoblotted (result not shown). When nuclear and cytosolic fractions of stimulated 10T1/2 cells were studied by immunoblotting using anti-pERK1/2, both subtypes were equally phosphorylated, but the band corresponding to p42 ERK2 was predominantly nuclear, while the band corresponding to p44 ERK1 was predominantly cytosolic (result not shown). However, immunofluorescence stud-
ies using both anti-ERK1 and anti-pERK1/2 indicated that ERK1 and ERK2 were equally translocated to the nucleus upon stimulation.

**Nuclear translocation of phosphorylated ERK is inhibited in TTA-treated 10T1/2 cells**

Treating cells with factors like PDGF, TPA, or 10% FBS activates the cell-signaling pathway leading to phosphorylation and subsequent nuclear translocation of ERK. This translocation step is transient and the duration of the nuclear accumulation depends on the stimuli and the cell type. Immunofluorescence confocal microscopy showed that the cellular localization of ERK1 was identical in resting control and TTA-treated 10T1/2 cells (Fig. 2). However, the translocation of ERK1 into the nucleus in response to mitogenic factors was quantitatively decreased and delayed in TTA-treated cells compared with control cells. In control cells, the majority of ERK1 was transported to the nucleus within 5 min of stimulation with 1.7 µM TPA, followed by a slow decrease in the level of nuclear ERK at 10 and 15 min. In TTA-treated cells, practically no translocation could be seen after 5 min (Fig. 2), and the maximum nuclear accumulation of ERK1, which was reached 10 to 15 min after stimulation, was considerably lower than the maximum level in control cells. At most, ERK1 appeared approximately equally distributed between the cytoplasm and the nucleus in TTA-treated cells (Fig. 2). Nuclear accumulation of ERK1 was similarly delayed in TTA-treated cells in response to 10% FBS or PDGF-BB (Results not shown). These experiments were repeated using antibodies against ERK2 with comparable results as for ERK1, indicating that in 10T1/2 cells, ERK1 and ERK2 follow a similar pattern of activation, translocation, and dephosphorylation in response to mitogenic factors (results not shown). By use of a monoclonal antibody against phosphorylated p44/42 ERK1/2 (pERK1/2), we demonstrated that in TTA-treated cells stimulated with FBS for 5 min, the cytoplasmic ERK was in fact in a phosphorylated state (Fig. 3). The latter observation was consistent with the enzyme activity results (Fig. 1). Thus, ERK was fully activated in TTA-treated cells, but the accumulation in the nucleus in response to mitogenic factors appeared strongly impaired.

**TTA mediates inhibition of nuclear import, and decrease in the level of pERK1/2 dephosphorylation**

In several cell lines, nuclear entry of ERK in response to mitogenic factors is followed by rapid dephosphorylation and nuclear export (33). Also, it has been shown that the accumulation of ERK1/2 in the nucleus is dependent on the neosynthesis of short-lived nuclear anchoring proteins (34). Thus, the decrease in the nuclear accumulation of ERK in TTA-treated cells could be caused by an increase in the export rate, or inability to retain phosphorylated ERK in the nucleus. In control cells, phosphorylated ERK1/2 reached maximal nuclear accumulation after 5–15 min of agonist stimulation (10% FBS). After 15 to 30 min, the nuclear pERK1/2 signal started to decrease and was lost within 45 min, but pERK1/2 was still present in the cytoplasm (Fig. 4). Only background staining was observed 2 h after agonist treatment. In TTA-treated cells, pERK1/2 did not accumulate to the same extent in the nucleus as was the case in control cells and the staining of the pERK1/2 persisted in the cytoplasm of the agonist treated cells for more than 2 h (Fig. 4). Immunoblot analysis with anti-pERK1/2 confirmed the results from the immunofluorescence experiment (data not shown). Thus, inhibition of pERK1/2 nuclear accumulation was coupled to decreased dephosphorylation. Since, in 10T1/2 cells, nuclear ERK export was much slower than its rate of import, the low level of nuclear accumulation after agonist stimulation of TTA-treated cells were most likely due to delayed entry of ERK.

ERK in its inactive state has been shown to interact with the MAPK kinase MEK, which contains a nuclear export signal (NES) and is located in the cytoplasm (35). Upon activation, pERK disconnects from MEK and is actively transported into the nucleus as a dimer (20). In addition, it has been shown that a dimerization-deficient mutant of ERK was able to enter the nucleus, but not when fused to β-galactosidase, indicating passive diffusion of the monomeric form (21). Leptomycin B (LMB) treatment specifically blocks all nuclear export signal (NES)-mediated export by interacting irreversibly with exportin 1 (CRM1) (36, 37). This leads to nuclear accumulation of the NES-protein/nucleocytoplasmic shuttling protein MEK, and thus unphosphorylated ERK1/2 will enter the nucleus by an unknown mechanism, possibly in complex with MEK (21). After 2 h of LMB treatment, ERK1 was predominately nuclear in control 10T1/2 cells (Fig. 5B). This accumulation was delayed in TTA-treated cells (Fig. 5E), further substantiating the interpretation that TTA affected and delayed nuclear import. In addition, these results...

---

**Fig. 1.** Mitogen-activated protein/extracellular signal-regulated kinase (ERK) activity in tetracelthioacetic acid (TTA)-treated versus control cells. 10T1/2 cells were grown to confluence in low-fat medium in the presence of 10 µM TTA or 10 µl aceto (control) with final medium change minimum 24 h before harvesting. Cells were stimulated with 1 unit platelet-derived growth factor-BB (PDGF-BB) for 5 or 30 min and lysed in a non-ionic detergent buffer (Materials and Methods). ERK was immunoprecipitated using rabbit polyclonal anti-ERK1, and mitogen-activated protein (MAP) kinase assay was performed as described in Materials and Methods using myelin basic protein as a substrate. Samples were subjected to SDS-PAGE and electrophoretically onto a nitrocellulose membrane and radioactivity was quantified using a phospho-imager (Instant Imager, Packard Electronic Autoradiography/ Instant Image Scanner).
showed that the delay in nuclear import was not restricted to the import of dimerized pERK2. Two hour LMB-treatment followed by 5 min stimulation with 10% FBS led to strong nuclear accumulation of ERK in control cells and a more moderate nuclear accumulation in TTA-treated cells (Fig. 5C, F). With prolonged LMB treatment total nuclear accumulation of ERK could be obtained in TTA-treated cells.

TTA generates changes in nuclear membrane fatty acid composition

The fatty acid composition of the nuclear membrane was determined (Table 1). The analysis demonstrated a high content of TTA (43%), confirming previous findings that CoA-esters of TTA is located in the nucleus (38). As a consequence, the total mole percent of saturated fatty acid increased in TTA-treated versus control cells. The total mol% of unsaturated fatty acid was decreased about 50% in TTA-treated cells, resulting in an increased ratio of saturated/unsaturated fatty acids and decreased double bond index (DBI). A small but significant amount of Δ⁸-desaturated TTA was found in the nuclear membrane fraction (Table 1). The percentage of total polyunsaturated fatty acids was slightly increased in TTA-treated cells. This was consistent in both n-6 and n-3 series, as well as in individual long chained polyunsaturated fatty acids. Table 1 also shows the fatty acid composition in the post-nuclear membrane fraction of TTA-treated 10T1/2 cells. This cellular fraction also contained high level of TTA, but the ratio of saturated fatty acids to monounsaturated fatty acids was not as dramatically changed as seen in the nuclear membrane fraction. In contrast to the nuclear membrane, the ratio of 18:1n-9/18:0 was increased in cellular membranes of TTA-treated cells, indicating that Δ⁸-desaturase activity was increased by addition of TTA. The ratio of 16:1n-7/16:0 was also increased 2-fold in both nuclear and the post-nuclear fraction. Moreover, the double bond in-

Fig. 2. Inhibition of ERK nuclear accumulation in response to 12-O-tetradecanoyl phorbol-13-acetate (TPA) treatment in TTA-treated cells. 10T1/2 cells grown to confluence in low-fat medium in the presence or absence of 10 μM TTA were reseeded onto coverslips and grown under the same conditions for at least 3 days to make sure no mitogenic factors remained in the cell-medium. Cells were then treated with 1.7 μM TPA for 5, 10, or 15 min, and fixed according to Materials and Methods. Cells were stained for indirect immunofluorescence using rabbit polyclonal anti-ERK1 and visualized using fluorescein (FITC)-conjugated goat-anti-rabbit antibodies. Cells were viewed through a 40× lens using confocal microscopy. The left panel shows the localisation of ERK1 in control cells while the right panel shows the localisation in TTA-treated cells. All images are from the middle layer of the cells, and are representative of at least 10 individual experiments. Images of individual cells represent the nucleocytoplasmic ERK distribution in 80–90% of the cells in a typical experiment.

Fig. 3. Activated ERK is excluded from the nucleus of TTA-treated cells. 10T1/2 cells grown in the presence or absence of TTA were treated with 10% FBS for 10 min and subjected to indirect immunofluorescence using a monoclonal antibody to p44/42 ERK1/2 combined with Biotin-conjugated goat-anti-mouse antibodies followed by FITC-streptavidine. Cells were viewed through a 40× lens and images were collected from the middle sections of the cells using confocal microscopy. The left panel shows the localisation of p44/42 ERK1/2 in control cells while the right panel shows the localisation in TTA-treated cells. The images of untreated cells show background staining. All images are representative of at least three individual experiments.
dex indicates that the relative increase in saturation was higher in nuclear than in post-nuclear membranes.

**Nuclear translocation of PKCα and β1 was inhibited in TTA-treated cells**

We have previously shown that, in contrast to PDGF-BB, TPA generates a major rearrangement of PKCα and β1 in 10T1/2 cells, including translocation into the nucleus (25). We now show that treatment of cells with 10% FBS also generated nuclear translocation of PKCβ1 (Fig. 6) and PKCα (Results not shown). We used this observation to examine whether the inhibition of entry into the nucleus was specific for ERK, or if other proteins traversing the nuclear membrane were affected by TTA. Nuclear translocation of PKCα and β1 in response to TPA or serum was delayed in TTA-treated cells (Fig. 6), demonstrating that the inhibition of entry into the nucleus is a feature affecting other signal pathway proteins in addition to ERK. Treatment of 10T1/2 cells with the cytoskeleton-disrupting agent colchicine showed that nuclear translocation of PKCβ1 and ERK1/2 depended on an intact cytoskeleton (results not shown). We also studied the translocation of the signal transduction proteins Abl, Stat1, and Stat5a since they are known to enter the nucleus upon stimulation in several cell lines. However, in 10T1/2 cells these proteins did not show any major rearrangement in response to the different mitogenic factors used (results not shown).

**TTA has a differential effect on protein translocation across the nuclear membrane**

The pathways of the proteins studied so far have not been completely elucidated, and neither ERK1/2 nor PKCα and β1 contain a known NLS. To study the import of a protein with a classical NLS, an in vitro semi-intact cell free assay was used (31). The NLS from SV40 large T antigen was chemically fused to BSA together with the flu-
The pre-mRNA binding protein hnRNP A1 shuttles con-
tinuously in and out of the nucleus (39), but is predomin-
antely localized to the nucleoplasm (Fig. 8A, D). In order to study its nuclear import, we treated 10T1/2 cells with Actinomycin D, which gave a mixed cytoplasmic and nu-
uclear localization of hnRNP A1 in the treated cells (Fig. 8B, E). In 2–5% of the cells, the cytoplasmic signal was strong and these cells were used to determine the effect of TTA on hnRNP A1 translocation. When Actinomycin D was removed, RNA synthesis and thus the nuclear localization of hnRNP A1 was recovered (40), so that after 20 min a 30% decrease in cells with strong cytoplasmic staining was seen (not shown), and after 1 h no strong cytoplasmic staining remained (Fig. 8C, F). Cell-fractionation and sub-
sequent SDS-PAGE and immunoblotting supported the results from the immunofluorescence experiment (not shown). Thus, as demonstrated in Fig. 8, and consistent with the in vitro results (Fig. 7), TTA-treatment had no ev-
ident effect on the import kinetics of the classical NLS-
containing protein hnRNP A1.

The expression of mRNAs encoding proteins involved in
nuclear import is not affected by TTA-treatment

It has previously been shown that TTA affects the level of expression of genes involved in the fatty acid metabo-
olism (6, 8, 10, 11). Therefore, the possibility of a TTA-
mediated down-regulation of proteins important for trans-
port across the nuclear membrane had to be investigated. Dot-blot analysis was carried out to analyze the level of RNA expression of the import factors Importin α, Importin β, Importin 7, and nuclear transport factor 2 (NTF2).

DNA fragments acquired by PCR of cDNA from 10T1/2
cells using specific primers for importin α, importin β, im-
portin 7, and NTF2 were dotted onto the membranes, with
actin as the reference gene (Fig. 9). Hybridization reac-
tions were carried out using a 32P-labeled first-strand cDNA probe prepared from RNA purified from 10T1/2
cells with/without TTA-pre-treatment. Quantification of the results showed no significant variations in the relative expression level of the studied import factors in TTA-
treated versus control cells (Fig. 9). In addition, cDNA from 10T1/2 cells with/without TTA-pre-treatment was subjected to semi-quantitative PCR using a combination of the primers for the actin gene and the genes of the differ-
ent import factors. The results obtained by semi-quantita-
tive PCR confirmed the Dot-blot analysis (result not shown).

**DISCUSSION**

The thia-fatty acid TTA causes a marked decrease in
TPA and PDGF-BB induced c-fos mRNA expression. We have earlier shown that TTA has a prominent effect on phospholipid metabolism in 10T1/2 cells by increasing the incorporation of inorganic phosphate into glicer-
ophospholipids, particularly phosphatidylethanolamine (4).

TTA-containing glicerophospholipids are slightly more hydrophilic than glicerophospholipids containing natural acyl groups (2). The dominating finding in the present
study regarding the fatty acid composition was the overall decrease in monounsaturated fatty acids after TTA treatment. The latter may be biologically important, particularly the substantial decrease in oleic acid (C18:1n-9). The predominant incorporation of TTA into membrane lipids may be due to its slow oxidation rate relative to naturally occurring monounsaturated fatty acids (41). This change in fatty acid composition is indicative of a more rigid membrane since oleic acid is known to favor the hexagonal over the lamellar structure of membranes (42). In addition, TTA is believed to have saturated fatty acid properties and, therefore, substituting TTA for oleic acid or

Fig. 6. The nuclear translocation of protein kinase C (PKC)α and PKCβ1 in response to FBS is inhibited in TTA-treated 10T1/2 cells. A: 10T1/2 cells were grown in the presence or absence of TTA. For studies of PKCβ1 translocation, cells were incubated with 10% FBS for 10 min, and for studies of PKCα translocation, cells were incubated with 1.7 μM TPA for 15 min. Cells were fixed as described in Materials and Methods. The localization of PKCβ1 was visualized using anti-PKCβ1 antibodies, and the localization of PKCα was visualized using anti-PKCα antibodies, both combined with FITC-conjugated anti-rabbit antibodies. Images were viewed through a 40× lens and collected from the middle section of the cells using confocal microscopy. B: The total amount of PKCα was determined by immunoblot analysis. Cells with or without TTA in the medium were grown to confluence with final medium change 24 h prior to harvesting. The cells were incubated with 1.7 μM TPA and lysed. About 20 μg of protein was separated on 10% SDS-PAGE gels and subsequently blotted onto nitrocellulose membranes. Membranes were incubated with rabbit polyclonal antibodies against c-PKCα (1:500, v/v). Bound antibodies were visualized using HRP-conjugated anti-rabbit IgG followed by enhanced chemoluminescence (ECL) detection using X-Ray film.

Fig. 7. Nuclear import of nuclear localization signal (NLS)-BSA-FITC is not inhibited in permeabilized TTA-treated cells compared with control cells. Prior to the in vitro semi intact cell free assay, 10T1/2 cells were grown in the presence or absence of TTA and reseeded on glass-cover slips. Twenty-four hours later, digitonin-permeabilization was performed as described in Materials and Methods. Permeabilized cells were then incubated for 5, 15, or 30 min with the NLS from SV40 large T fused to BSA-FITC in the presence of ATP and reticulocyte lysate. In addition, cells were incubated for 30 min with NLS-BSA-FITC and ATP without reticulocyte lysate present. Cells were then fixed and mounted, as described in the Immunofluorescence procedure. Images were viewed through a 40× lens and collected from the middle section of the cells using confocal microscopy.
other unsaturated fatty acids, would favor the more rigid lamellar structure. Taken together, the present data and the previous finding that some PE species increase in TTA-treated cells indicate that the TTA-effect may be lipid species specific.

There were many potential candidate steps where the PDGF-mediated signal transduction pathway leading to c-fos expression could be disrupted by TTA. Previous experiments have shown that TTA can be incorporated into the second messenger diacylglycerol (DAG) (S. A. Eiane, C. Helleland, R. K. Berge, J. R. Lillehaug, and H. Holmisen, personal communication), and thereby create a DAG that activates PKC poorly. If this was the most prominent effect of TTA, the TPA-induced signal transduction pathway would not be affected since TPA mimics, and replaces, DAG in activating PKC directly (43). The attenuation of TPA-mediated c-fos mRNA expression in TTA-treated cells (12) argues against a DAG effect and suggests that TTA might alter lipid and/or membrane composition important for PKC mediated signal transduction downstream of DAG synthesis.

MAPK assays showed that ERK was fully activated after TPA and PDGF-BB stimulation in both TTA-treated cells and control-cells (Fig. 1). These results suggest that TTA does not affect the signal transduction pathway upstream of ERK. Considering that ERK needs to pass through the nuclear membrane pores in order to phosphorylate and activate nuclear factors, alterations in the nuclear membrane structure could affect pore function and thus ERK translocation. We found a marked decrease in the translocation of phosphorylated ERK1/2 in TTA-treated cells compared with control cells (Figs. 2 and 3). There did not seem to be any difference in the activation pattern of ERK1 and ERK2, nor in the susceptibility to the TTA-caused inhibition of import. Thus, our results indicate that treating the cells with a non-β-oxidizable fatty acid markedly attenuates the ERK1/2 nuclear accumulation through an unknown mechanism, which could explain the inhibition of c-fos expression. TTA generates dramatic changes in the membrane ratio of saturated to monounsaturated fatty acids, especially in the nuclear membrane, and this may affect pore function. Lipid modification may play an important role in the membrane association of the cytoskeleton and it is known that about one third of ERK is associated with the microtubule cytoskeleton (44). Immunofluorescence studies of Actin and β-tubulin architecture showed no major differences in control cells and TTA-treated cells (result not shown). We can, however, not conclude that the cytoskeleton in TTA-treated cells is not altered, but it may be altered in a manner we cannot observe with the techniques we have used.

To see whether TTA inhibited the nuclear import of ERK1/2, or affected their export, we treated the cells with Leptomycin B (Fig. 5). The relocalisation of dephosphorylated ERK from the nucleus to the cytoplasm is coupled to the export of MEK (33), which contains a nuclear export signal (NES) (45). Thus, no export of ERK will take place when the NES-pathway is blocked. In the presence of LMB, a distinctive slower nuclear accumulation of ERK1/2 could be seen in TTA-treated cells compared with control cells. Since the entry of ERK in response to LMB most likely takes place as a MEK-ERK complex (21), and probably uses a different pathway from the dimeriza-
tion-dependent pERK1/2 pathway, the LMB results are consistent with a nuclear import of ERK through different pathways, inhibited by TTA. However, with prolonged LMB treatment, total nuclear accumulation of ERK was obtained in TTA-treated cells. We also showed that dephosphorylation of ERK was delayed in TTA-treated cells compared with control cells, indicating a slower level of dephosphorylation when ERK had decreased access to the nuclear compartment. The main part of ERK1/2 dephosphorylation takes place in the nucleus (46), and our results are consistent with this.

Our results show that in addition to ERK, TTA significantly inhibits the nuclear import of PKCa and PKCB1. The mechanisms for ERK1/2 nuclear import appear to share some common features with PKCa and PKCB1 nuclear import since they are all cytoskeleton dependent (results not shown, 47, 48). In comparison, it has been shown that the import of BSA coupled to a canonical NLS is not cytoskeleton dependent (47). There are indications that the import mechanism of PKC does not follow the usual NLS-guided pathway, since Schmalz et al. (49) have shown that the nuclear translocation of PKCα is not linked to the classical import factors Importin β and RanGTP. However, there is an energy-dependent step, and the rate of the nuclear translocation, as well as the size of the proteins, are arguments for an active translocation mechanism and against uptake by free diffusion (49). In contrast, ERK import seems to be dependent on both Importin β and RanGTP, shown by use of the inhibitors wheat germ agglutinin and RanQ69L (21). Also, a homolog of ERK in Drosophila, D-ERK, has been linked to import factors Dim-7 and Ketel, homologs of vertebrate Importin 7 and Importin β, respectively (50). Consistent with these findings is the possibility that ERK may be imported through the direct interaction with the NPC (22, 23). If this latter mechanism is active, then changes in membrane lipid composition may cause alterations to the NPC thereby inhibiting nuclear ERK import.

In the present report, we demonstrate that TTA-treatment affects the import of two classes of proteins known to use different nuclear import pathways. Thus, our data indicate that the inhibition of nuclear translocation is not restricted to one transport pathway, but is rather related to a more general perturbation of the nuclear import machinery. However, the in vitro nuclear import of a reporter protein linked to the canonical NLS sequence from SV40 large T antigen, and the in vivo import of the NLS (M9)-containing protein hnRNP A1, was not inhibited in TTA-treated cells (Fig. 8). As proteins containing a NLS use classical import pathways, which are different from the pathways used by the PKs studied here, TTA may have a differential effect depending on the nature and/or strength of the import signal and on the factors involved in the import through the NPC. Since the gene expression of four essential transport factors was not affected by TTA-treatment (Fig. 9), we hypothesize that TTA replaces naturally occurring monounsaturated fatty acids, especially oleic acid, producing more lamellar, and rigid, nuclear membrane structures perturbing efficient trans-

The authors wish to thank Mrs. H. Kanestrøm and Ms. I. Hageberg for their devoted technical assistance. The project is supported by grants from the Norwegian Cancer Society (B.B. and C.H.); the Norwegian Research Council; and the Locus on Cancer Research, the Faculty of Medicine, University of Bergen.

REFERENCES

1. Berge, R. K., and E. Hvattum. 1994. Impact of cytochrome P450 system on lipoprotein metabolism. Effect of abnormal fatty acids (3-thia fatty acids). Pharmacol. Ther. 61: 345–383.
2. Skrede, S., H. N. Sorensen, L. N. Larsen, H. H. Steinegger, K. Ho, vik, O. S. Spydevold, R. Horn, and J. Bremer. 1997. Thia fatty acids, metabolism and metabolic effects. Biochim. Biophys. Acta. 1344: 115–131.
3. Kryvi, H., A. Aarsland, and R. K. Berge. 1990. Morphologic effects of sulfur-substituted fatty acids on rat hepatocytes with special reference to a proliferation of peroxisomes and mitochondria. J. Struct. Biol. 103: 257–265.
4. Skorde, J., D. Asiedu, A. C. RUSTAN, C. A. Drevon, A. Shurbaji, and R. K. Berge. 1990. Regulation of fatty acid oxidation and triglyceride and phospholipid metabolism by hypolipidemic sulfur-substituted fatty acid analogues. J. Lipid Res. 31: 1627–1635.
5. Aarsland, A., and R. K. Berge. 1991. Peroxisome proliferating sul-
phur- and oxy-substituted fatty acid analogues are activated to acyl
coenzyme A thioesters. Biochem. Pharmacol. 41: 53–61.
6. Raspe, E., L. Madsen, A. M. Lefebvre, I. Leitersdorfer, L. Gelman, J. Peinado Onsurbe, J. Dallongeville, J. C. Frucht, R. Berge, and B. Staels. 1999. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. J. Lipid Res. 40: 2099–2110.
7. Asiedu, D. K., A. Shurbaji, A. C. RUSTAN, I. Bjorkhem, L. Berglund, and R. K. Berge. 1995. Hepatic fatty acid metabolism as a
determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids. Eur. J. Biochem. 227: 713–722.
8. Demoz, A., H. Vaagenes, A. Aarsaether, E. Hvattum, J. Skorde, M. Gottlicher, J. R. Lillehaug, G. G. Gibson, J. A. Gustafsson, and S. Hood. 1994. Coordinate induction of hepatic fatty acyl-CoA oxidi
dase and P4504A1 in rat after activation of the peroxisome proliferator-activated receptor (PPAR) by sulfur-substituted fatty acid analogues. Xenobiotica. 24: 945–956.
9. Madsen, L., A. Garza, G. Asins, D. Serra, F. G. Hegardt, and R. K. Berge. 1999. Mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase and carnitine palmitoyltransferase II as potential control sites for ketogenesis during mitochondrial and peroxisome proliferation. Biochim. Pharmacol. 57: 1011–1019.
10. Madsen, L., and R. K. Berge. 1999. 3-Thia fatty acid treatment, in
counter to cicosapentaenoic acid and starvation, induces gene ex-
pression of carnitine palmitoyltransferase-II in rat liver. Lipids. 34: 447–456.
11. Vaagenes, H., L. Madsen, D. K. Asiedu, J. R. Lillehaug, and R. K. Berge. 1998. Early modulation of genes encoding peroxisomal and mitochondrial beta-oxidation enzymes by 3-thia fatty acids.
12. Helleland, C., S. A. Eiane, R. K. Berge, H. Holmsen, and J. R. Lillehaug. 1997. 1-(Carboxymethylthio)tetradecane attenuates PDGF-
and PPARalpha induction and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. J. Lipid Res. 40: 2099–2110.
13. Chen, R. H., C. Sarneeki, J. Blenis. 1992. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 12: 915–927.
14. Gonzalez, F. A., A. Seth, D. L. Raden, D. S. Bowman, F. S. Fay, and
16. Hill, C. S., R. Marais, S. John, J. Wynne, S. Dalton, and R. Treisman. 1993. Functional analysis of a growth factor-responsive transcription factor complex. Cell. 73: 395–406.

17. Brunet, A., D. Roux, P. Lenormand, S. Dowd, S. Keyse, and J. Pousseysegur. 1999. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18: 664–674.

18. Fukuda, M., Y. Gotoh, and E. Nishida. 1997. Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J. 16: 1901–1908.

19. Blanco-Aparicio, C., J. Torres, and R. Pulido. 1999. A novel regulatory mechanism of MAP kinases activation and nuclear translocation mediated by PKA and the PTP-SL tyrosine phosphatase. J. Cell Biol. 147: 1129–1136.

20. Khokhlatchev, A. V., B. Canagarajah, J. Wilsbacher, M. Robinson, M. Atkinson, E. Goldsmith, and M. H. Cobb. 1998. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell. 93: 605–615.

21. Adachi, M., M. Fukuda, and E. Nishida. 1999. Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer. EMBO J. 18: 3547–3556.

22. Matsubayashi, Y., M. Fukuda, and E. Nishida. 2001. Evidence for existence of a nuclear pore complex-mediated, cytosol-independent pathway of nuclear translocation of ERK MAP Kinase in permeabilized cells. J. Biol. Chem. 276: 41755–41760.

23. Whitehurst, A. W., J. L. Wilsbacher, Y. You, K. Luby-Phelps, M. S. Moore, and M. H. Cobb. 2002. ERK2 enters the nucleus by a carrier-independent mechanism. Proc. Natl. Acad. Sci. USA. 99: 7496–7501.

24. Meili, R., and K. Ballmer-Hofer. 1996. Activation-independent nuclear translocation of mitogen activated protein kinase ERK1 mediated by thiol-modifying chemicals. FEBS Lett. 394: 34–38.

25. Bjornstad, B., C. Helleland, and J. R. Lillehaug. 2000. Differential TPA and PDGF-BB effects on subcellular localisation of PKC alpha and beta I in C3H/10T1/2 cells. Anticancer Res. 20: 2635–2640.

26. Male, R., J. R. Lillehaug, R. Djurhuus, and I. F. Pryme. 1959. A rapid method of total lipid extraction and purification. J. Cell Biol. 148: 849–856.

34. Lenormand, P. C. Sardet, G. Pages, G. L’Allemain, A. Brunet, and J. Pousseysegur. 1995. Growth factors induce nuclear translocation of MAP kinases (p42/p44 and p44/p42) but not of their activator MAP kinase kinase (p42/p44) in fibroblasts. J. Cell Biol. 122: 1079–1088.

35. Tchoukoukoski, N. S., P. Ş. Shapiro, S. Goueli, and N. G. Ahn. 1999. Nuclear localization of mitogen-activated protein kinase kinase 1 (MEK1) is promoted by serum stimulation and G2-M progression. Requirement for phosphorylation at the activation lip and signaling downstream of M KK1. J. Biol. Chem. 274: 6168–6174.

36. Fukuda, M., S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, and E. Nishida. 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390: 308–311.

37. Wolff, B. J., J. S. Sangler, and Y. Wang. 1997. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo- cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4: 139–147.

38. Elholm, M., A. Garras, S. Neve, D. Tornehave, T. Lund, J. Skovre, T. Flatmark, K. Kristiansen, and R. K. Berge. 2000. Long-chain acyl-CoA esters and acyl-CoA binding protein are present in the nucleus of rat liver cells. J. Lipid Res. 41: 538–545.

39. Pinol-Roma, S., and G. Dreyfuss. 1992. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature. 353: 730–732.

40. Vautier, D., P. Chesne, C. Cunha, A. Calado, J. P. Renard, and M. Carmona-Fonseca. 2001. Transcription-dependent nucleocytoplasmic distribution of hnRNP A1 protein in early mouse embryos. J. Cell Sci. 114: 1521–1531.

41. Hvattum, E., H. J. Grav, and J. Bremer. 1993. Hormonal and substrate regulation of 3-thia fatty acid metabolism in Morris 7800 C1 hepatoma cells. Biochem. J. 294: 917–921.

42. Rillofs, L., G. Lindblom, A. Wieslander, and A. Christensson. 1984. Lipid bilayer stability in biological membranes. In Biomembranes, Membrane Fluidity. M. Kates and L. A. Manson, editors. Plenum Press, New York and London. 205–245.

43. Nishizuka, Y. 1984. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 308: 693–698.

44. Reszka, A. A., R. Seger, C. D. Diltz, E. G. Krebs, and E. H. Fischer. 1995. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc. Natl. Acad. Sci. USA. 92: 8881–8885.

45. Fukuda, M., Y. Gotoh, Y. Gotoh, and E. Nishida. 1996. Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J. Biol. Chem. 271: 20024–20028.

46. Todd, J. L., K. G. Tanner, and J. M. Denu. 1999. Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J. Biol. Chem. 274: 13271–13280.

47. Schmalz, D., F. Kalkbrenner, F. Hucho, and K. Buchner. 1996. Transport of protein kinase C alpha into the nucleus requires intact cytoskeleton while the transport of a protein containing a canonical nuclear localization signal does not. J. Cell Sci. 109: 2401–2406.

48. Martelli, A. M., L. Cocco, R. Bareggi, G. Tabellini, R. Rizzoli, M. D. Ghibellini, and P. Narducci. 1999. Insulin-like growth factor-dependent stimulation of nuclear phospholipase C-betal activity in Swiss 3T3 cells requires an intact cytoskeleton and is paralled by increased phosphorylation of the phospholipase. J. Cell. Biochem. 72: 339–348.

49. Schmalz, D., F. Hucho, and K. Buchner. 1998. Nuclear import of protein kinase C occurs by a mechanism distinct from the mechanism used by proteins with a classical nuclear localization signal. J. Cell Sci. 111: 1823–1830.

50. Lorenzen, J. A., S. E. Baker, F. Denhez, M. B. Melnick, D. L. Brower, and L. A. Perkins. 2001. Nuclear import of activated ERK by DIM-7, an importin family member encoded by the gene moleksin. Development. 128: 1405–1414.